Arvinas, Inc.
Financials
Valuation Metrics
Arvinas, Inc.'s Market Cap is $486M. At end of 2025 it was $770M. Ranked #2734 of 3,118 in US market (top 88%), #1190 of 1,474 on NASDAQ (top 81%), #213 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 80%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $486M | US#2,734/3,118 Sec#213/265 |
| Revenue | $317M | US#2,403/3,118 Sec#91/265 |
| Net Income | $9M | US#2,158/3,118 Sec#71/265 |
| Total Assets | $675M | US#2,641/3,118 Sec#135/265 |
| Net Assets | $562M | US#2,148/3,118 Sec#99/265 |
| Employees | 246 | US#2,446/3,118 Sec#121/265 |
| Value | ||
| P/E | 52.31x | US#1,937/3,118 Sec#53/265 |
| P/B | 0.87x | US#324/3,118 Sec#18/265 |
| P/S | 1.54x | US#1,095/3,118 Sec#20/265 |
| EV/EBITDA | 138.07x | US#2,452/3,118 Sec#81/265 |
| FCF Yield | -42.92% | US—/3,118 Sec—/265 |
| Profitability | ||
| ROE | 1.65% | US#2,036/3,118 Sec#63/265 |
| ROA | 1.38% | US#1,810/3,118 Sec#67/265 |
| Op. Margin | -4.45% | US#2,439/3,118 Sec#82/265 |
| Revenue Growth | -15.05% | US#2,604/3,118 Sec#144/265 |
| Financial Health | ||
| Debt Ratio | 20.08% | US#224/3,118 Sec#76/265 |
| Total Debt | $8M | US#2,844/3,118 Sec#204/265 |
| FCF | $-209M | US#2,783/3,118 Sec#212/265 |
| Cash | $94M | US#2,263/3,118 Sec#179/265 |
| Current Ratio | 7.91x | US#316/3,118 Sec#98/265 |
| Net Debt/EBITDA | -29.69x | US#7/3,118 Sec#1/265 |
| Performance | ||
| 1Y Return | -25.64% | US#2,431/3,118 Sec#193/265 |
| 1M Return | 1.75% | US#1,619/3,118 Sec#97/265 |
| From 52W High | -48.04% | US#2,519/3,118 Sec#188/265 |
| 1Y MDD | -50.69% | US#2,424/3,118 Sec#166/265 |
| Trading | ||
| Volume | 951,280 shares | US#2,001/3,118 Sec#197/265 |
| Trading Value | $7M | US#2,677/3,118 Sec#216/265 |
| Per Share | ||
| EPS | $0.14 | US#2,060/3,118 Sec#68/265 |
| BPS | $8.71 | US#1,926/3,118 Sec#79/265 |
Company Info
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.